Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | FSHR | P23945 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077188 | 0.89 | KMT2A (0.59) | NAMPTKMT2ASMN1; SMN2FSHRHDAC1 | |
| SCHEMBL6385896 | 0.87 | L3MBTL1 (0.60) | NAMPTKMT2ASMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL13213711 | 0.84 | SMN1; SMN2 (0.69) | NAMPTKMT2ASMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL4707395 | 0.84 | LMNA (0.75) | NAMPTKMT2ASMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL6076554 | 0.84 | KMT2A (0.55) | NAMPTKMT2ASMN1; SMN2USP2FSHR | |
| SCHEMBL22874495 | 0.83 | HDAC1 (0.58) | NAMPTSMN1; SMN2ALDH1A1LMNAHDAC1 | |
| SCHEMBL212371 | 0.83 | HDAC1 (0.56) | HDAC1HDAC3 | |
| SCHEMBL6068990 | 0.82 | SMN1; SMN2 (0.69) | NAMPTKMT2ASMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL9367173 | 0.79 | LMNA (0.69) | NAMPTKMT2ASMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL10194836 | 0.79 | SMN1; SMN2 (0.73) | NAMPTKMT2ASMN1; SMN2USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592667-A2 | NEW MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069803-A2 | MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES AND THEIR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | claimed |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-08-19 | — | — | US | claimed |
| US-7501451-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7071219-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060089403-A1 | Mono-acylated o-phenylendiamines derivatives | FERTIG GEORG | 2006-04-27 | — | — | US | disclosed |
| EP-1592667-A2 | NEW MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069803-A2 | MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES AND THEIR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089403-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC10, HDAC11 | NAMPT 1017/4885KMT2A 24/4885SMN1; SMN2 4107/4885 |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC11, HDAC10 | NAMPT 2040/4885KMT2A 33/4885SMN1; SMN2 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.